Home > Publications Database > Sex difference in evolution of cognitive decline: studies on mouse model and the Dominantly Inherited Alzheimer Network cohort. > print

001     257575
005     20240309115311.0
024 7 _ |a pmc:PMC10097702
|2 pmc
024 7 _ |a 10.1038/s41398-023-02411-8
|2 doi
024 7 _ |a pmid:37045867
|2 pmid
024 7 _ |a altmetric:145753469
|2 altmetric
037 _ _ |a DZNE-2023-00455
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kommaddi, Reddy Peera
|0 0000-0002-5874-944X
|b 0
245 _ _ |a Sex difference in evolution of cognitive decline: studies on mouse model and the Dominantly Inherited Alzheimer Network cohort.
260 _ _ |a London
|c 2023
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1684845792_10421
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Women carry a higher burden of Alzheimer's disease (AD) compared to men, which is not accounted entirely by differences in lifespan. To identify the mechanisms underlying this effect, we investigated sex-specific differences in the progression of familial AD in humans and in APPswe/PS1ΔE9 mice. Activity dependent protein translation and associative learning and memory deficits were examined in APPswe/PS1ΔE9 mice and wild-type mice. As a human comparator group, progression of cognitive dysfunction was assessed in mutation carriers and non-carriers from DIAN (Dominantly Inherited Alzheimer Network) cohort. Female APPswe/PS1ΔE9 mice did not show recall deficits after contextual fear conditioning until 8 months of age. Further, activity dependent protein translation and Akt1-mTOR signaling at the synapse were impaired in male but not in female mice until 8 months of age. Ovariectomized APPswe/PS1ΔE9 mice displayed recall deficits at 4 months of age and these were sustained until 8 months of age. Moreover, activity dependent protein translation was also impaired in 4 months old ovariectomized APPswe/PS1ΔE9 mice compared with sham female APPswe/PS1ΔE9 mice. Progression of memory impairment differed between men and women in the DIAN cohort as analyzed using linear mixed effects model, wherein men showed steeper cognitive decline irrespective of the age of entry in the study, while women showed significantly greater performance and slower decline in immediate recall (LOGIMEM) and delayed recall (MEMUNITS) than men. However, when the performance of men and women in several cognitive tasks (such as Wechsler's logical memory) are compared with the estimated year from expected symptom onset (EYO) we found no significant differences between men and women. We conclude that in familial AD patients and mouse models, females are protected, and the onset of disease is delayed as long as estrogen levels are intact.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Amyloid beta-Protein Precursor
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Infant
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Mice, Transgenic
|2 MeSH
650 _ 2 |a Sex Characteristics
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: genetics
|2 MeSH
650 _ 2 |a Fear
|2 MeSH
650 _ 2 |a Memory Disorders
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Amyloid beta-Protein Precursor: genetics
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DIAN-20090101
|5 EXP:(DE-2719)DIAN-20090101
|e Longitudinal Study on Dominantly Inherited Alzheimer's Disease
|x 0
700 1 _ |a Verma, Aditi
|b 1
700 1 _ |a Muniz-Terrera, Graciela
|b 2
700 1 _ |a Tiwari, Vivek
|b 3
700 1 _ |a Chithanathan, Keerthana
|b 4
700 1 _ |a Diwakar, Latha
|b 5
700 1 _ |a Gowaikar, Ruturaj
|b 6
700 1 _ |a Karunakaran, Smitha
|b 7
700 1 _ |a Malo, Palash Kumar
|b 8
700 1 _ |a Graff-Radford, Neill R
|b 9
700 1 _ |a Day, Gregory S
|0 0000-0001-5133-5538
|b 10
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 11
|u dzne
700 1 _ |a Vöglein, Jonathan
|0 P:(DE-2719)2811820
|b 12
|u dzne
700 1 _ |a Nübling, Georg
|0 P:(DE-2719)9001761
|b 13
|u dzne
700 1 _ |a Ikeuchi, Takeshi
|0 0000-0001-8828-8085
|b 14
700 1 _ |a Kasuga, Kensaku
|0 0000-0002-2178-0769
|b 15
700 1 _ |a Network, Dominantly Inherited Alzheimer
|b 16
|e Collaboration Author
700 1 _ |a Ravindranath, Vijayalakshmi
|0 0000-0003-3226-0782
|b 17
773 _ _ |a 10.1038/s41398-023-02411-8
|g Vol. 13, no. 1, p. 123
|0 PERI:(DE-600)2609311-X
|n 1
|p 123
|t Translational Psychiatry
|v 13
|y 2023
|x 2158-3188
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/257575/files/DZNE-2023-00455.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/257575/files/DZNE-2023-00455.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:257575
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811820
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)9001761
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TRANSL PSYCHIAT : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:09:41Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:09:41Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-26
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T09:09:41Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-18
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b TRANSL PSYCHIAT : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-18
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser 1
|l Parkinson Genetics
|x 0
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger 1 ; AG Höglinger 1
|l Translational Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1111016
|k Clinical Dementia Research München ; AG Levin
|l Clinical Dementia Research München Levin
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1110002
980 _ _ |a I:(DE-2719)1111016
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21